Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Incyte

Incyte
Regional

Incyte Announces New Employee Stock Awards Under 2024 Inducement Plan

May 15, 2025May 14, 2025 - by Timothy Alexander

WILMINGTON, DE — Incyte (Nasdaq: INCY) announced it granted restricted stock unit awards (RSUs) totaling 33,413 shares of common stock and stock options to purchase 8,951 shares to 60 new …

Incyte Announces New Employee Stock Awards Under 2024 Inducement Plan Read More

Incyte
Regional

Incyte to Present at 2025 BofA Securities Health Care Conference

May 8, 2025May 6, 2025 - by Timothy Alexander

WILMINGTON, DE — Incyte (Nasdaq: INCY) announced its participation in the 2025 BofA Securities Health Care Conference. The company’s presentation is scheduled for Tuesday, May 13, 2025, at 1:40 PM …

Incyte to Present at 2025 BofA Securities Health Care Conference Read More
Incyte
Regional

Incyte Reports Strong Q1 2025 Financial Results and Pipeline Progress

May 7, 2025May 5, 2025 - by Timothy Alexander

WILMINGTON, DE — Incyte (Nasdaq: INCY) delivered strong first-quarter financial results for 2025, propelled by revenue growth across its key products and continued advances in its clinical portfolio. Total revenues …

Incyte Reports Strong Q1 2025 Financial Results and Pipeline Progress Read More

Incyte
Regional

Incyte to Showcase Latest Oncology Advancements at 2025 ASCO Meeting

April 29, 2025April 27, 2025 - by Timothy Alexander

WILMINGTON, DE — Incyte (Nasdaq: INCY) has announced that multiple abstracts highlighting data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual …

Incyte to Showcase Latest Oncology Advancements at 2025 ASCO Meeting Read More
Incyte
Regional

Incyte Grants Restricted Stock Units to New Employees

April 14, 2025April 14, 2025 - by Timothy Alexander

WILMINGTON, DE — Biopharmaceutical company Incyte (Nasdaq: INCY) recently awarded restricted stock units (RSUs) totaling 20,334 shares of common stock to 24 newly hired employees. These awards were granted as …

Incyte Grants Restricted Stock Units to New Employees Read More

Incyte
Regional

Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment

March 23, 2025March 23, 2025 - by Timothy Alexander

WILMINGTON, DE — Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials evaluating povorcitinib, an oral JAK1 inhibitor, for moderate to severe hidradenitis suppurativa …

Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment Read More

Posts pagination

Previous 1 … 7 8

Trending News

  • HHS Directs $77 Million to Behavioral Health Programs

  • VA Cemeteries Mark 25 Years Since 9/11 With Service Day

  • Welcome Home Our Vietnam Veterans to Saint Simon and Jude on September 19.

  • Coatesville to Mark 25th Anniversary of 9/11 With Memorial Service

  • Coatesville Area Ordered to Cut Water Use Up to 15%

Subscribe for Updates

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

VA National Cemeteries

VA Cemeteries Mark 25 Years Since 9/11 With Service Day

September 7, 2026September 6, 2026

Veteran

Welcome Home Our Vietnam Veterans to Saint Simon and Jude on September 19.

September 7, 2026September 7, 2026

Cardiology

SBA Rebrands ICHRAs to Push Health Option for Small Firms

September 7, 2026September 6, 2026

Copyright © 2026 MyChesCo.